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Abstract
Objective
The objective of this study was to develop and characterize alginate microspheres suitable
for embolization with on-demand triggered doxorubicin (DOX) release and whereby the
microspheres as well as the drug releasing process can be visualized in vivo using MRI.
Methods and Findings
For this purpose, barium crosslinked alginate microspheres were loaded with temperature
sensitive liposomes (TSL/TSL-Ba-ms), which release their payload upon mild hyperthermia.
These TSL contained DOX and [Gd(HPDO3A)(H2O)], a T1 MRI contrast agent, for real time
visualization of the release. Empty alginate microspheres crosslinked with holmium ions
(T2*MRI contrast agent, Ho-ms) were mixed with TSL-Ba-ms to allow microsphere visuali-
zation. TSL-Ba-ms and Ho-ms were prepared with a homemade spray device and sized by
sieving. Encapsulation of TSL in barium crosslinked microspheres changed the triggered
release properties only slightly: 95% of the loaded DOX was released from free TSL vs.
86% release for TSL-Ba-ms within 30 seconds in 50% FBS at 42°C. TSL-Ba-ms (76 ±
41 μm) and Ho-ms (64 ± 29 μm) had a comparable size, which most likely will result in a sim-
ilar in vivo tissue distribution after an i.v. co-injection and therefore Ho-ms can be used as
tracer for the TSL-Ba-ms. MR imaging of a TSL-Ba-ms and Ho-ms mixture (ratio 95:5)
before and after hyperthermia allowed in vitro and in vivo visualization of microsphere depo-
sition (T2*-weighted images) as well as temperature-triggered release (T1-weighted
images). The [Gd(HPDO3A)(H2O)] release and clusters of microspheres containing hol-
mium ions were visualized in a VX2 tumor model in a rabbit using MRI.
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Conclusions
In conclusion, these TSL-Ba-ms and Ho-ms are promising systems for real-time, MR-
guided embolization and triggered release of drugs in vivo.
Introduction
Liver cancer is the fifth most frequently diagnosed cancer in men and the second most frequent
cause of cancer death, worldwide. Among primary liver cancers, hepatocellular carcinoma
(HCC) represents the major histological subtype, accounting for 70 to 85% of the total liver
cancer burden worldwide [1]. More than 700.000 cases of this malignant disease are diagnosed
yearly with a five year survival of less than 5% [2]. Nowadays, surgical resection is the primary
curative therapy for patients with HCC. Unfortunately, only 20–35% of the patients are eligible
for partial resection or liver transplantation and the recurrence rate is high [3–5]. Additionally,
systemic chemotherapy is mostly ineffective for these patients because only low drug concen-
trations are reached in the tumor, while the treatment results in severe adverse events and
patient morbidity [2,6].
Transarterial chemoembolization (TACE) is a more effective treatment modality than sys-
temic chemotherapy and principally used for inoperable HCC patients [6,7]. During the
TACE procedure, a catheter is positioned in the arterial supply of a tumor via which a che-
motherapeutic drug is administered followed by embolic particles [8,9]. These embolic parti-
cles block the feeding vessels of the tumor and restrict nutrient and oxygen supply to the
tumor cells. In addition, the blockage of the blood vessels by the embolic particles reduces
the washout of the chemotherapeutic drug, which results in higher drug concentrations in
the tumor area (i.e. increased efficacy) and reduced systemic exposure (i.e. less side effects)
[9,10].
Recently, drug eluting beads (DEBs), which consist of embolic particles with sizes ranging
from 70–150 μm to 500–700 μm and loaded with a chemotherapeutic drug, have been devel-
oped for TACE procedure [9,11,12], delivering the embolic particles and the chemotherapeutic
drugs at once [13–15]. One of the clinically used DEB formulations is based on crosslinked
polyvinyl alcohol (PVA) modified with sulfonic acid groups to obtain negatively charged
microspheres (DC beads1). A high drug concentration of positively charged cytostatics such
as doxorubicin and irinotecan can be achieved in these PVA DEBs via an ion exchange mecha-
nism [12,16,17]. Clinical trials have shown that embolization with DEBs leads to a significant
reduction in peak plasma concentrations of doxorubicin [18,19] while increasing the antitumor
efficacy compared to conventional TACE [20,21].
A drawback of these clinically used DEBs is, however, that they lack the ability to be visual-
ized both during and after administration. Therefore, it is not possible to monitor the micro-
sphere distribution in the tumor tissue, which is likely a very important factor for the
treatment efficacy. Furthermore, the beads which are currently used for chemoembolization
display a sustained release profile leading to low drug concentrations in the tumor over long
periods of time (weeks) [17,22]. In contrast, it was recently shown by several studies that rapid
intravascular release of doxorubicin from temperature sensitive liposomes leads to high intra-
vascular drug concentrations, which subsequently enhances the drug penetration into the
tumor [23–25]. This approach may lead to 20–30 times higher total drug deposition in tumor
tissue compared to free drug administration and 5 times more than a Doxil-like formulation
[26,27] thereby improving antitumor efficacy [26,28].
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Therefore, the objective of this study was to develop and characterize microspheres that
combine embolization with on-demand temperature triggered drug release and whereby the
microspheres as well as the drug releasing process can be visualized. To this end, we previously
encapsulated temperature sensitive liposomes in alginate microspheres [29]. Alginate micro-
spheres have been used for arterial embolization [30,31] and showed to be excellent emboliza-
tion agents in the short term as well as the long term [28,31,32]. Furthermore, MR imaging
agents were incorporated in the microspheres (i.e. holmium ions; T2 contrast agent) as well as
in the liposomes (i.e [Gd(HPDO3A)(H2O)]; T1 contrast agent) allowing the visualization of
both the microspheres and the triggered drug release. In this article we take this concept to a
next level by encapsulating a cytostatic drug (doxorubicin) and a contrast agent in the lipo-
somes. Unfortunatly, the system described in our previous study [29] is not compatible with
doxorubicin release since holmium ions used for crosslinking the alginate microspheres ham-
per doxorubicin release (see results and discussion section). Here a novel approach is presented
that allows for triggered doxorubicin release as well MR image guidance of the holmium-con-
taining microspheres. The physicochemical and imaging characteristics of the improved sys-
tem, a dispersion consisting of TSL loaded in barium crosslinked alginate microspheres
(TSL-Ba-ms) and empty microspheres crosslinked with holmium ions (Ho-ms), were mea-
sured in vitro (Fig 1). Moreover, the applicability of this system was evaluated in vivo in a VX2
Fig 1. Schematic representation of temperature sensitive liposomes (TSL) loaded in alginate microspheres crosslinked with barium ions (TSL-Ba-
ms). The TSL are loaded with doxorubicin (DOX) and [Gd(HPDO3A)(H2O)] (T1 MRI contrast agent). The DOX and [Gd(HPDO3A)(H2O)] are released from
the TSL-Ba-ms during mild hyperthermia. The release of [Gd(HPDO3A)(H2O)] can be monitored by MRI. Empty alginate microspheres crosslinked with
holmium ions (T2*MRI contrast agent, Ho-ms) are co-injected with TSL-Ba-ms to allow microsphere visualization by MRI.
doi:10.1371/journal.pone.0141626.g001
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tumor in the auricle of a New Zealand White rabbit. In this study a water bath was used for
applying hyperthermia temperatures (~42°C) to the tissue, since the tumor was easy accessible.
For deep lying tumors MR guided high intensity focused ultrasound (HIFU) would be the
method of choice for heating the tumor [33–35].
Materials and Methods
Materials
The phospholipids 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), and 1,2-distearoyl-
sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000] (DSPE-PEG2.000)
were purchased from Lipoid GmbH, Ludwigshafen, Germany, and 1-stearoyl-2-hydroxy-sn-
glycero-3-phosphocholine (MSPC) was obtained from Avanti Polar Lipids, Alabaster, U.S.A.
Doxorubicin-HCl was purchased from Guanyu Bio-technology Co., LTD, Xi’an, China. [Gd
(HPDO3A)(H2O)] (Prohance
1) was acquired from Bracco Diagnostic Inc., Monroe Town-
ship, U.S.A. Barium chloride dehydrate, Triton X-100, zinc sulfate heptahydrate, fetal bovine
serum and ethylenediaminetetraacetic acid disodium salt dihydrate (EDTA) were purchased
from Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands. Holmium chloride hexahy-
drate was obtained fromMetall rare earth limited, Shenzhen, China. Sodium alginate (Manucol
LKX) was a gift from FMC biopolymer, Philadelphia, U.S.A.
Liposome preparation
Temperature sensitive liposomes (TSL) were prepared via the well-known lipid film hydration
method as described previously [36,37]. DPPC, MSPC and DSPE-PEG2.000 were dissolved in
chloroform (15 mL) in a molar ratio of 86:10:4. Chloroform was evaporated under reduced
pressure to form a lipid film. Residual chloroform was removed overnight under a nitrogen
flow. Next, the lipid film was hydrated in 20 mL 120 mM ammonium sulfate (pH 5.4) contain-
ing 375 mM [Gd(HPDO3A)(H2O)] at 60°C for 15 minutes (80 μmol phospholipids/mL). The
liposomal dispersion was extruded through two 200 nm filters (2 times) and two 100 nm filters
(8 times). The continuous phase of the liposome dispersion was substituted by 20 mMHEPES
buffer pH 7.4 containing 8 g NaCl/L via a PD-10 gel filtration column. The liposomes (15 mL)
were remotely loaded with doxorubicin (DOX, 15 mL, 5 mg/mL) at 37°C for 90 minutes at a
pH of 7.4 [36]. Unencapsulated DOX and [Gd(HPDO3A)(H2O)] were removed by ultracentri-
fugation (125.000 g for 45 min at 4°C). The liposomes were resuspended in 20 mMHEPES
buffer pH 7.4 (15 mL) at a DOX concentration of 5 mg/mL.
Liposome characterization
Dynamic light scattering (DLS, Malvern ALV CGS-3 system) was used to determine the size of
the liposomes and their polydispersity index. Intensity correlation functions were measured
using a wavelength of 632.8 nm and a scattering angle of 90°. The measurements were per-
formed in 20 mMHEPES buffer pH 7.4 at 25°C.
In order to measure the loading efficiency, liposomes were disrupted with Triton X-100
(0.1% final concentration) and the DOX concentration in the samples was determined using
fluorescence measurements (excitation wavelength 485 nm, emission wavelength 600 nm
FLUOstar Optima, BMG Labtech). A calibration curve of DOX from 0 to 6 μg/mL in 20 mM
HEPES buffer pH 7.4 containing 0.1% Triton X-100 was used to determine the DOX concen-
trations in the samples.
The temperature triggered release of DOX was measured by the change in fluorescence
intensity in time (3 hours) at 37 and 42°C (excitation wavelength 468 nm, emission wavelength
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558 nm, Fluorolog connected to a water bath, Horiba scientific). DOX-loaded liposomes (1 μL)
were added to preheated (2 mL) 20 mMHEPES buffer (pH 7.4) or 50% fetal bovine serum
(FBS) at 37 or 42°C. Triton X-100 (10%, 20 μL) was added at the end of the experiment to
destroy remaining liposomes and thereby release the DOX which was still encapsulated. The
percentage DOX release at both temperatures was calculated using the following equation: (It-
I0)/(ITX-I0)100 in which It is the fluorescence intensity at time t, I0 the intensity at the start of
the experiment and ITX the fluorescence intensity after addition of Triton X-100.
Alginate microsphere preparation
The experimental setup for the preparation of alginate microspheres consisted of a homemade
spraying device connected to a collecting vessel which is displayed in Fig 2. The spraying device
Fig 2. Experimental setup for the preparation of alginate microspheres. (A) Schematic representation of the experimental setup. An alginate
solution (3% w/v in 20 mMHEPES buffer pH 7.4 containing 8 NaCl/L) is transferred into a syringe and introduced in the spraying system via a syringe pump
(1.5 mL/min) which are connected via a plastic tube. Alginate droplets are formed by passing nitrogen gas (0.8 Bar) through the nozzle. The droplets are
collected in a crosslinking solution (containing 100 mM barium chloride or holmium chloride). Photos of experimental setup (B) and nozzle (C).
doi:10.1371/journal.pone.0141626.g002
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consisted of a syringe pump connected to a glass nozzle via plastic tubing. Furthermore, a
nitrogen flow was connected to the nozzle to induce the formation of droplets.
All types of alginate microspheres used in this study (i.e. barium crosslinked microspheres
encapsulating TSL and empty microspheres crosslinked with barium ions or holmium ions)
were prepared with the following protocol. An alginate solution (3% w/v in 20 mMHEPES
buffer pH 7.4) was passed through the nozzle (1.5 mL/min) simultaneously with nitrogen gas
(0.8 Bar) to form alginate droplets. The droplets were hardened in a crosslinking solution con-
taining 100 mM barium chloride or 100 mM holmium chloride. The microspheres were
allowed to solidify for 2 hours in the crosslinking solution and subsequently they were sized
with a 300 μm sieve to remove large microspheres and aggregates. In a second sieving step, the
microspheres were collected on a 50 μm sieve and washed 3 times with 20 mMHEPES buffer
pH 7.4 (in total 500 mL).
Microspheres loaded with TSL were prepared by mixing 6% alginate (w/v, in 20 mM
HEPES buffer pH 7.4) in a 1:1 (w/w) ratio with TSL (resulting in a final alginate solution of 3%
w/v containing 40 μmol phospholipids/mL). The alginate droplets were hardened in 20 mM
HEPES buffer containing 100 mM barium chloride to form TSL-Ba-ms. Empty alginate micro-
spheres crosslinked with barium ions (Ba-ms) were prepared by spraying the alginate solution
(3% w/v) in 20 mMHEPES buffer pH 7.4 containing 100 mM barium chloride. Alginate
microspheres crosslinked with holmium ions (Ho-ms) were prepared by spraying the alginate
solution in a crosslinking aqueous solution of 100 mM holmium chloride.
Microsphere characterization
Morphological examination and size distribution determination of the microspheres before
and after sieving were investigated with fluorescence (TSL-Ba-ms) and bright-field (Ho-ms)
microscopy (BZ-9000, Keyence equipped with a GFP BP filter with an excitation wavelength of
472–30 nm and an emission wavelength of 520–35 nm and a Plan Fluor 20x lens, Nikon). The
images were analyzed with calibrated BZ II Analyzer software to determine the diameter of the
microspheres. The average size of the microspheres was based on the measured diameter of
500 microspheres.
In order to determine the DOX concentration in the TSL-Ba-ms, 30 mg of wet TSL-Ba-ms
was disrupted in 20 mL ethylenediaminetetraacetic acid (EDTA, 5% w/v in reverse osmosis
water) containing 0.1% Triton X-100. Subsequently, the DOX concentration in TSL-Ba-ms
was determined by fluorescence measurements as described above.
The DOX release kinetics from TSL-Ba-ms were examined at 37 and 42°C whereby the
DOX concentration in the samples was measured by UPLC. Preheated medium (20 mL, 20
mM HEPES buffer pH 7.4 or 50% FBS) at 37 or 42°C was added to TSL-Ba-ms (75 mg wet
weight) and samples (1.5 mL) were taken in time. Subsequently, the samples were mixed
with the same volume of cold (4°C) 20 mM HEPES buffer pH 7.4 to prevent further leakage
of DOX. The samples were divided into two vials; one vial was used to determine the
amount of DOX released and the second vial was used to determine the total amount of
DOX.
Release samples (1 mL) containing FBS were centrifuged (2000 g, 5 min, 4°C) to sediment
the microspheres. Acetonitrile (0.25 mL) and an aqueous solution of ZnSO4 (0.6 gr/mL, 35 μL)
were added to the supernatant (0.75 mL) to precipitate proteins [38] and avoid clogging of the
UPLC column, followed by another centrifugation step. An aqueous solution of ZnSO4 (0.6 gr/
mL, 45 μL), acetonitrile (333 μL) and Triton X-100 (10%, 10 μL) were added to the second vial
containing 1 mL sample for the determination of the total amount DOX present in the FBS
samples. These samples were also centrifuged prior to UPLC measurements.
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Release samples in HEPES buffer were centrifuged and 0.25 mL acetonitrile was added to
0.75 mL supernatant. EDTA (5%, 2 mL) and Triton X-100 (10%, 20 μL) were added to the sec-
ond vial containing 1 mL sample for the determination of the total amount DOX. Subse-
quently, the samples were centrifuged and 0.25 mL acetonitrile was added to 0.75 mL
supernatant.
DOX concentrations in the TSL-Ba-ms samples were determined by UPLC using a BEH
C18 1.7 μm column (Waters) at 50°C and a fluorescence detector (excitation wavelength 480
nm, emission wavelength 585 nm). The eluent consisted of 1% perchloric acid and 25% aceto-
nitrile in milli-Q water at an elution rate of 0.5 mL/min. The injection volume was 7.5 μL and
the chromatographic runtime per sample was 3 minutes.
Magnetic resonance imaging (MRI) was used to visualize the Ho-ms and to monitor the
temperature triggered [Gd(HPDO3A)(H2O)] release from the TSL-Ba-ms. Four different sam-
ples were imaged (i.e. TSL-Ba-ms:Ho-ms (95:5 and 100:0), and Ba-ms:Ho-ms (95:5 and 100:0))
before and after mild hyperthermia (15 minutes at 42°C) using the MRI sequences as described
below. This allows distinguishing of the contribution of each component in this system (i.e.
[Gd(HPDO3A)(H2O)], barium and holmium ions) on the MRI visualization of microspheres
and/or [Gd(HPDO3A)(H2O)] release.
Magnetic resonance imaging
All MRI experiments were performed on a clinical 1.5-Tesla MR scanner (Achieva; Philips
Health care) with an 8 elements head coil (in vitro experiment) or a 47 mmmicroscopy coil (in
vivo experiment).
The following MR sequences were used in this study: T1-weighted MR images were obtained
using a spin echo sequence (TR = 450 ms, TE = 18 ms, FA = 90°, turbo-factor = 3, 16 slices,
voxel size = 0.30x0.30x2.0 mm3). T2-weighted MR images were obtained using a 3D gradient
echo sequence (TR = 15.1 ms, TE = 9.20 ms, FA = 30°, 32 slices, voxel size = 0.30x0.30x1.0
mm3). Furthermore, T1-maps were obtained by sampling the signal recovery after inversion
using a Look-Locker (LL) sequence (TR = 7.44 ms, TE = 3.5 ms, FA = 5°, turbo-factor = 5, 1
slice, voxel size = 0.80×0.80×3 mm3, 50 timepoints at 60 ms interval).
The images obtained from each LL measurement were automatically fitted with in-house
developed Matlab software (7.12, The MathWorks Inc., Natick, MA, USA, 2000). The temporal
evolution of the magnitude of the longitudinal magnetization (M) was fitted (Levenberg-Mar-
quardt algorithm) for each pixel with the following equation:
M ¼ jA ðAþ BÞ  et=T1 j ð1Þ
Where T1 is the apparent longitudinal relaxation rate, t is the time after the inversion pulse
and A and B are constants. The sample T1 differs from T1 by an offset only dependent on flip
angle (α) and delay between 2 consecutive excitation pulses (Δt):
1
T1
¼ 1
T1
þ lnðcos aÞ=Dt ð2Þ
Finally, T2-maps were obtained by sampling the signal decay using a multi-echo gradient
echo sequence (TR = 100 ms, TE1 = 8 ms, ΔTE = 8 ms, 8 echos, FA = 90°, turbo-factor = 8, 1
slice, voxel size = 0.80×0.80×3 mm3).
For the in vitro experiment (see section 2.5) the samples were placed in a sample holder con-
taining water, which was placed in the middle of the 8 elements head coil for imaging. For the
in vivo experiment (see section 2.8) the tumor bearing ear was placed in the middle of a 4.7 cm
microcoil.
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For T1 and T2 quantification one square ROI (5x5 pixels) was manually selected inside the
microsphere pellet and supernatant before and after heating.
Animal model
All experimental protocols were conducted in agreement with the Netherlands Experiments on
Animals Act and the European convention guidelines, and reviewed and approved by the Ani-
mal Experiments Committee Utrecht, the Netherlands (2012.III.05.043).
Female New ZealandWhite rabbits (2.5–3.5 kg) were purchased from Charles River, France.
All rabbits were allowed to acclimatize for at least one week before use.
VX2 tumor cells [39,40] were propagated in both flanks of a New Zealand White rabbit
(analgesia with 4 mg/kg Carprofen1). The tumor was removed under analgesia and sedation
(Carprofen1 4 mg/kg, Dexdormitor1 0.125 mg/kg and Narketan1 15 mg/kg) when reaching
a tumor diameter of ~ 3 cm. A VX2 cell suspension was generated by dissecting and fragment-
ing tumor tissue using a cellstrainer (Easystrainer 100 μm, Greiner). A tumor in the auricle of a
New Zealand White rabbit was induced by injecting 200 μL of the cell suspension (8.5x108
cells/mL PBS) subcutaneously into the auricle of the rabbit under analgesia and anesthesia
(Carprofen1 4 mg/kg, Dexdormitor1 0.125 mg/kg and Narketan1 15 mg/kg).
In vivo imaging
When the tumor in the auricle reached a diameter of ~2 cm after 2 weeks the in vivo imaging
study was performed. Carprofen1 (4 mg/kg, 0.25 mL), Dexdormitor1 (0.125 mg/kg, 0.75 mL)
and Narketan1 (15 mg/kg, 0.45 mL) were administered subcutaneously for analgesia and anes-
thesia. The rabbit was positioned in the MRI scanner with the tumor bearing auricle in a warm
water bath at 37°C. A dispersion of 152 mg TSL-Ba-ms and 8 mg Ho-ms suspended in 1 mL
mMHEPES buffer pH 7.4 was injected intratumorally. Next, the water bath in which the
tumor was positioned, was heated up to 46°C (such that the interior of the tumor reached at
least 42°C) for 15 minutes to induce release of [Gd(HPDO3A)(H2O)]. T1 and T2-weighted
images and T1 and T2 maps were made (as described in section 2.6) prior to the injection of
the microspheres and immediately after the intratumoral injection of the microspheres as well
as after the incubation at elevated temperatures.
Results and Discussion
Preparation and characterization of temperature sensitive liposomes
encapsulating doxorubicin (DOX) and [Gd(HPDO3A)(H2O)]
Temperature sensitive liposomes (TSL) containing lysolipids were prepared via the lipid film
hydration method (the characteristics of the TSL are described in Table 1) [36,37]. These TSL
were passively loaded with [Gd(HPDO3A)(H2O)] (a T1 MRI contrast agent) during hydration
of the lipid film and subsequently remotely loaded with doxorubicin (DOX). The mean
Table 1. Characteristics of temperature senstitive liposomes (TSL) loaded with DOX and [Gd
(HPDO3A)(H2O)].
TSL
Lipid composition DPPC:MSPC:DSPE-PEG2.000
Molar ratio lipids (feed ratio) 86:10:4
Mean diameter (PDI) 134 nm (0.09 +/- 0.02)
DOX encapsulation (%) >99%
doi:10.1371/journal.pone.0141626.t001
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diameter of the liposomes was 134 nm with a PDI 0.1. The encapsulation efficiency of DOX
was> 95% as expected for remotely loaded liposomes [36,41–43]. [Gd(HPDO3A)(H2O)] was
passively loaded into the liposomes and has therefore an encapsulation efficiency around 10%
[29].
Fig 3 shows the release of DOX from TSL before encapsulation in the alginate microspheres
as a function of incubation time at 37 and 42°C in 20 mMHEPES buffer pH 7.4 (Fig 3A) and
in 50% fetal bovine serum (FBS) (Fig 3B), respectively. TSL released less than 10% of their con-
tent after 3 hours incubation in HEPES buffer at 37°C while at 42°C complete release took
place within 30 seconds. In 50% FBS at 37°C, the TSL showed a release of ~15% within 5 min-
utes and reached 30% release after 3 hours. The release rate at 37°C in 50% FBS was higher
than in HEPES buffer (Fig 3A and 3B) likely because proteins destabilized the lipid bilayer
[44–46]. At 42°C more than 95% of the loaded DOX was released within 30 seconds in 50%
FBS (Fig 3B), which is comparable with the release of DOX in HEPES buffer at the same tem-
perature, indicating that DOX is released nearly quantitatively at 42°C independent of the pres-
ence of proteins in the release medium.
Fig 3. Temperature triggered release of DOX from TSL. Temperature triggered release of DOX from TSL (DPPC:MSPC:DSPE-PEG2.000 86:10:4) in 20
mM HEPES buffer pH 7.4 (A) or 50% fetal bovine serum (B) at 37 and 42°C. Temperature triggered DOX release from TSL-Ba-ms in 20 mMHEPES buffer
pH 7.4 (C) and 50% FBS (D) at 37 and 42°C.
doi:10.1371/journal.pone.0141626.g003
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Preparation of barium crosslinked alginate microspheres loaded with
TSL (TSL-Ba-ms)
Alginate microspheres containing TSL were prepared with the spraying device shown in Fig 2.
An alginate solution containing TSL was sprayed into 20 mMHEPES buffer pH 7.4 containing
100 mM barium chloride. The mean diameter of the unfractionated TSL-Ba-ms was 30 μm
with a standard deviation of 21 μmwhile the mean diameter was 76 μmwith a standard devia-
tion of 41 μm after sieving (Fig 4C and 4D). This demonstrates that many microspheres had a
size below 50 μm, which were subsequently successfully removed by sieving. The encapsulation
efficiency of TSL into the alginate microspheres was 60% based on DOX measurements. This
relatively low encapsulation efficiency is based on the instability of TSL in the alginate solution
since alginate can be inserted into the lipid bilayer [47] leading to DOX leakage from the TSL
before formation of the TSL-Ba-ms. The presence of DOX loaded liposomes in the alginate
microspheres could also be qualitatively observed with fluorescence microscopy (Fig 4A).
Fig 4. Microscopy images and size distribution of TSL-Ba-ms and Ho-ms. Fluorescence microscopy image of TSL-Ba-ms (A) and bright-field
microscopy image of alginate microspheres crosslinked with holmium ions (Ho-ms) (B) after sieving. The size distribution of TSL-Ba-ms before (C) and after
(D) sieving was analyzed with calibrated BZ II Analyzer software.
doi:10.1371/journal.pone.0141626.g004
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Characterization of empty alginate microspheres crosslinked with
holmium ions
Empty microspheres crosslinked with solely holmium ions (Ho-ms) were prepared and sieved sim-
ilar to the TSL-Ba-ms described above. This resulted in Ho-ms with a mean diameter of 64 μm and
a standard deviation of 29 μm (Fig 4B), which is similar to the diameter of TSL-Ba-ms (Fig 4A).
Since, the chemical composition of the Ho-ms and TSL-Ba-ms are very similar, both consist mainly
of water (> 98%), the size is the dominant variable influencing their biodistribution upon intra-
arterial injection [48,49]. Considering the fact that Ho-ms and TSL-Ba-ms have a comparable size,
they most likely have a similar in vivo tissue distribution after an i.v. co-injection and therefore Ho-
ms can be used as tracer for the TSL-Ba-ms. The concentration of holmium ions in the Ho-ms is
relatively low, therefore the toxicity of these microspheres is expected to be low [29,30].
Release of doxorubicin (DOX) from TSL-Ba-ms
The release of DOX from TSL-Ba-ms at 37 and 42°C in 20 mMHEPES buffer pH 7.4 (Fig 3C)
and the same buffer with 50% FBS (Fig 3D) was evaluated over a time period of 3 hours. At
37°C, TSL-Ba-ms displayed a marginal release (20%) of DOX after incubation in HEPES buffer
for 3 hours. At 42°C, approximately 75% of DOX was released within 30 seconds while a maxi-
mum release of 85% was achieved after 1 minute in HEPES buffer. This incomplete DOX
release from TSL-Ba-ms in HEPES buffer (containing 0.8% NaCl) is most likely due to the
interaction of positively charged DOX and negatively charged alginate. Addition of Triton X-
100 did not lead to extra release of DOX which would be the case if some liposomes remained
intact after applying mild hyperthermia. The incomplete release of DOX was also observed
visually since TSL-Ba-ms remained slightly pink after incubation at 42°C.
In 50% FBS, TSL-Ba-ms showed a DOX release of 30% after 3 hours incubation at 37°C. At
42°C however, the TSL-Ba-ms released DOX nearly quantitatively within 3 minutes. The differ-
ence in DOX release found in HEPES and 50% FBS can be explained by the presence of proteins.
Presumably, proteins in the release medium desorb DOX from the negatively charged alginate
since it is reported in other studies that DOX can interact with plasma proteins [50,51].
Previously, we prepared microspheres containing liposomes which were crosslinked with bar-
ium as well as holmium ions in a molar ratio of 95:5 [29]. When TSL containing DOX were
loaded into these microspheres, no release of DOX occurred upon mild hyperthermia (Figure A
in S1 File). Likely, the released DOX interacted with the holmium ions present in the micro-
spheres since a color shift from red to purple was observed during incubation at 42°C (Figure A in
S1 File). This holmium-DOX complexation was reported previously [52,53] and also evidenced
by the fact that the purple color of a solution containing DOX and holmium ions returned to red
after the addition of EDTA, which captures the holmium ions (data not shown). Thus it was con-
cluded that DOX was released from the liposomes during mild hyperthermia, however the forma-
tion of holmium ion-DOX complexes prevented the release of DOX from the microspheres.
In the current approach DOX might also interact with Ho-ms after being released from the
TSL-Ba-ms. However, only 5% of the DOX was captured after 5 minutes incubation with Ho-
ms (Figure B in S1 File). Furthermore, It is expected that the DOX upon release from the TSL
will diffuse quickly out of the microspheres into the tumor tissue. Therefore, the influence of
the Ho-ms on the efficacy of DOX will be minimal.
Visualization of microspheres and [Gd(HPDO3A)(H2O)] release by MRI
As mentioned in the introduction holmium ions and [Gd(HPDO3A)(H2O)] are MRI contrast
agents that allow visualization of the microspheres and triggered drug release, respectively. To
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investigate in more detail the contribution of each component in our system (i.e. barium ions,
holmium ions and [Gd(HPDO3A)(H2O)]) on the MR signal, T1 and T2-weighted (wt) MR
images were obtained of i) TSL-Ba-ms mixed with Ho-ms (ratio 95:5), ii) TSL-Ba-ms only, iii)
Ba-ms mixed with Ho-ms (ratio 95:5) and iv) Ba-ms only.
Fig 5 shows T2-wt and T1-wt MR images of these four combinations before and after incuba-
tion at mild hyperthermia (42°C for 15 minutes). The microspheres sedimented and the micro-
spheres were therefore present in a pellet at the bottom of the tube. As expected, the holmium
containing microspheres were clearly detectable as a black layer on the T2-wt image before and
after mild hyperthermia (Fig 5I, 5J, 5M and 5N), whereas microspheres containing barium only
(Ba-ms) were not observed on T2-wt images (Fig 5O and 5P). Interestingly, TSL-Ba-ms were
also clearly detectable on T2-wt images before hyperthermia because of the T2-effect of [Gd
(HPDO3A)(H2O)] at high concentrations (Fig 5K). However, upon temperature triggered release
and subsequent dilution of [Gd(HPDO3A)(H2O)], the T2-effect of gadolinium decreased and
the TSL-Ba-ms were no longer visible on the T2-wt image (Fig 5L). The temperature triggered
[Gd(HPDO3A)(H2O)] release was best visualized on T1-wt images (Fig 5A–5D). These images
show an increase in signal intensity in the microsphere pellet as well as in the supernatant of the
TSL-Ba-ms after applying mild hyperthermia (Fig 5B and 5D). This demonstrates that MRI
allows the visualization of the microspheres (containing holmium ions) as well as the release of
[Gd(HPDO3A)(H2O)] at the same location in an in vitro situation.
Additionally, quantitative T1 and T2-mapping was performed of the same samples
described above (i.e TSL-Ba-ms mixed with Ho-ms (ratio 95:5), TSL-Ba-ms only, Ba-ms mixed
with Ho-ms (ratio 95:5) and Ba-ms only) before and after mild hyperthermia (Fig 6). Further-
more, HEPES and a free [Gd(HPDO3A)(H2O)] solution, at approximately the same concen-
tration (0.5 mM) as obtained after [Gd(HPDO3A)(H2O)] release from the TSL-Ba-ms, were
included as control samples. Fig 6 shows the mean T1 and T2-values in a region of interest
Fig 5. T1 and T2*-weighted MR images of TSL-Ba-ms or Ba-msmixed with or without Ho-ms (ratio 95:5) before mild hyperthermia. T1 and T2*-
weighted MR images of TSL-Ba-ms or Ba-ms mixed with or without Ho-ms (ratio 95:5) before mild hyperthermia and after incubation at 42°C for 15 minutes.
Signal enhancement in the supernatant after mild hyperthermia indicates release of [Gd(HPDO3A)(H2O)] in the T1-wt image. The holmium ions appear
hypointense in the T2*-wt image due to local distortion of the magnetic field.
doi:10.1371/journal.pone.0141626.g005
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(ROI) postioned in the microsphere pellet (if present) or the supernatant. The T2-values of
the supernatant are not shown because they were too long (as expected for liquids lacking mac-
romolecules) to be adequately measured with the sequence used. The T1-value of the samples
containing TSL-Ba-ms decreased in the microsphere pellet as well as in the supernatant after
mild hyperthermia (Fig 6A and 6B). The T1-values of these samples after heating were the
same as the T1 of free [Gd(HPDO3A)(H2O)] at the same concentration in the microsphere pel-
let as well as in the supernatant, indicating quantitative release of [Gd(HPDO3A)(H2O)] from
TSL-Ba-ms after applying hyperthermia. As expected, Ba-ms did not show a change in T1-
value before and after applying mild hyperthermia. The presence of 5% Ho-ms had only a
minor effect on the T1-values of the microsphere pellet and the supernatant and therefore does
not interfere with the detection of released [Gd(HPDO3A)(H2O)]. In contrast, the T2-value of
samples containing Ho-ms was, as expected, very short in the presence of Ho-ms before and
after mild hyperthermia (Fig 6C). As explained previously, [Gd(HPDO3A)(H2O)] exhibits a
strong T2-effect at high concentrations (i.e. loaded in TSL). Therefore, the hyperthermia
Fig 6. T1 and T2* in the microsphere pellet and supernatant of alginate microspheres before and after mild hyperthermia. T1 in the microsphere
pellet (A) and supernatant (B) and T2* in the microsphere pellet (C) of alginate microspheres before and after mild hyperthermia (HT; 42°C for 15 minutes). A
region of interested (ROI) was positioned in the microsphere pellet (if present) or the supernatant to determine the T1 and T2*-values (Mean + standard
deviation).
doi:10.1371/journal.pone.0141626.g006
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triggered release of [Gd(HPDO3A)(H2O)] caused an increase of T2 in the TSL-Ba-ms pellet,
which confirms the necessity of Ho-ms for visualizing the microsphere distribution after apply-
ing hyperthermia, otherwise the microspheres would be no longer visible.
In vivo visualization of the release of [Gd(HPDO3A)(H2O)] and the
distribution of a TSL-Ba-ms and Ho-ms mixture in a VX2 tumor present in
the auricle of a rabbit
The feasibility of TSL-Ba-ms and Ho-ms (in a ratio of 95:5) to allow in vivomonitoring of the
microsphere deposition and [Gd(HPDO3A)(H2O)] release was evaluated in the auricle VX2
tumor of a rabbit after intratumoral injection of a dispersion containing TSL-Ba-ms as well as
Ho-ms. Implanting the tumor in the auricle of a rabbit made the tumor easy accessible for
hyperthermia treatment using a water bath. In addition, the hypothesis that the Ho-ms co-
localize with TSL-Ba-ms and therefore can be used as a tracer for TSL-Ba-ms, was investigated.
T1 and T2-wt images and T1 and T2-maps were made at 3 timepoints: i) before intratumoral
injection of the microspheres, ii) immediately after the intratumoral co-injection of TSL-Ba-ms
and Ho-ms (95:5 ratio) and iii) shortly after applying mild hyperthermia. The tumor tissue
looked relatively homogeneous on the T2-wt image prior to administration (Fig 7A).
Fig 7. T2*-wt images and T2*-maps of intratumoral injected TSL-Ba-ms and Ho-ms in a tumor in the auricle of a New ZealandWhite rabbit. T2*-wt
images (A-C) and T2*-maps (D-F) of a tumor in the auricle of a New ZealandWhite rabbit before (A, D) and after (B, E) intratumoral injection of TSL-Ba-ms
and Ho-ms. Finally, the tumor was heated in the range between 42 and 46°C for 15 minutes (C, F).
doi:10.1371/journal.pone.0141626.g007
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Intratumoral co-injection the dispersion of TSL-Ba-ms and Ho-ms (95:5) caused signal voids
on the T2-wt images indicating the presence of microsphere clusters in the tumor (Fig 7B).
These clusters were still visible as signal voids on the T2-wt images after applying mild hyper-
thermia for 15 minutes (Fig 7C). The T2-maps showed the same response: intratumoral co-
injection of the microspheres caused a shortening of the T2 in the tumor (Fig 7D and 7E),
whereas the application of hyperthermia did not influence the T2 of the tumor (Fig 7E and
7F).
No difference in tumor T1-values was observed after intratumoral co-injection of the micro-
sphere mixture (Fig 8A and 8B). This indicates that [Gd(HPDO3A)(H2O)] was not released
and thus the TSL loaded into the microspheres remained intact during the injection of the
microspheres. After the intratumoral co-injection of the microspheres, the tumor was heated
in the range between 42 and 46°C for 15 minutes to trigger the release of [Gd(HPDO3A)
(H2O)] from the liposomes and subsequently from the TSL-Ba-ms. A drop in T1-values was
observed in the tumor after applying hyperthermia, indicating release of [Gd(HPDO3A)
(H2O)] from the TSL-Ba-ms (Fig 8C). This observation is strengthened by the fact that the
intrinsic T1-value of tissue increase with increasing temperature [54,55].
Fig 8. T1-maps and T1-wt images of intratumoral injected TSL-Ba-ms and Ho-ms in a tumor in the auricle of a New ZealandWhite rabbit. T1-maps
(A-C) and T1-wt images (D-E) of a tumor in the auricle of a New ZealandWhite rabbit before (A,D) and after (B) intratumoral co-injection of TSL-Ba-ms and
Ho-ms. Finally, the tumor was heated in the range between 42 and 46°C for 15 minutes (C,E).
doi:10.1371/journal.pone.0141626.g008
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The T1-wt images showed the same response: the tumor tissue looked relatively homoge-
neous on the T1-wt image prior to administration (Fig 8D), whereas the co-injection of the
microspheres followed by applying hyperthermia caused a shortening in T1 (Fig 8E).
Furthermore, the location of Ho-ms (i.e. largest change in T2-value) corresponded very
closely with the location of the TSL-Ba-ms (i.e. largest change in T1-value) making Ho-ms a
suitable tracer for TSL-Ba-ms.
Conclusion
This paper shows that alginate microspheres encapsulating temperature sensitive liposomes
containing a T1 MRI contrast agent ([Gd(HPDO3A)(H2O)]) and doxorubicin (DOX)
(TSL-Ba-ms) were successfully developed. The encapsulation of TSL in Ba-ms changed the
triggered release properties only slightly. Also empty holmium (T2 MRI contrast agent) cross-
linked microspheres (Ho-ms) were prepared. The incorporation of MR imaging agents in the
microspheres (i.e. holmium ions in Ho-ms) as well as in the liposomes ([Gd(HPDO3A)(H2O)]
in TSL-Ba-ms) allowed for visualization of both the microspheres and the triggered drug
release in vitro using MRI. The microsphere deposition and [Gd(HPDO3A)(H2O)] release
after intratumoral co-injection of TSL-Ba-ms and Ho-ms was monitored in the VX2 tumor
model. The deposition of Ho-ms overlapped very closely with the location of the [Gd
(HPDO3A)(H2O)] release from TSL-Ba-ms making Ho-ms a suitable tracer for TSL-Ba-ms.
Since in this study only an intratumoral injection was performed the embolization properties
of our system were not characterized, though this will be addressed in a future study. Further-
more, we will investigate the antitumor efficacy of the proposed system compared to free DOX
and standard TACE.
Taken together, these microspheres are attractive systems for real-time, MR-guided emboli-
zation and triggered release of drugs.
Supporting Information
S1 File. Interaction of DOX and Ho-ms after DOX-release. Figure A shows temperature
triggered DOX release from TSL encapsulated in alginate microspheres crosslinked with bar-
ium ions and holmium ions in a 95:5 ratio. Figure B shows the uptake of DOX as function of
incubation time with Ho-ms.
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